Evidence map›Paper›PMID 33655249›Full record

ArticlebioRxiv : the preprint server for biology2021

The type 2 asthma mediator IL-13 inhibits SARS-CoV-2 infection of bronchial epithelium.

Luke R Bonser, Walter L Eckalbar, Lauren Rodriguez, Jiangshan Shen, Kyung Duk Koh, Lorna T Zlock, Stephanie Christenson, Prescott G Woodruff, Walter E Finkbeiner, David J Erle

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Luke R BonserLung Biology Center, Critical Care, Allergy and Sleep Medicine, Department of Medicine; University of California, San Francisco.
Walter L EckalbarLung Biology Center, Critical Care, Allergy and Sleep Medicine, Department of Medicine; University of California, San Francisco.
Lauren RodriguezUCSF CoLabs; University of California, San Francisco.
Jiangshan ShenLung Biology Center, Critical Care, Allergy and Sleep Medicine, Department of Medicine; University of California, San Francisco.
Kyung Duk KohLung Biology Center, Critical Care, Allergy and Sleep Medicine, Department of Medicine; University of California, San Francisco.
Lorna T ZlockDepartment of Pathology; University of California, San Francisco.
Stephanie ChristensonDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine; University of California, San Francisco.
Prescott G WoodruffDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine; University of California, San Francisco.
Walter E FinkbeinerDepartment of Pathology; University of California, San Francisco.
David J ErleLung Biology Center, Critical Care, Allergy and Sleep Medicine, Department of Medicine; University of California, San Francisco.
University of California, San Francisco · US

Funding

Understanding Asthma EndotypesU19AI077439 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRESCOTT G WOODRUFF · 2008 to 2026
$41.1M
SynthesisP30DK072517 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VERKMAN, ALAN S · 2005 to 2022
$18.1M
Airway epithelial cell gene regulation: new mechanisms and therapeutic strategiesR35HL145235 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ERLE, DAVID J · 2019 to 2025
$6.8M
Genetic variation impacting the airway smooth muscle in children with asthmaR00HL135403 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ECKALBAR, WALTER · 2020 to 2022
$747k
NHLBI NIH HHS R00 HL135403NHLBI NIH HHS R35 HL145235NIAID NIH HHS U19 AI077439NIDDK NIH HHS P30 DK072517
6 · The paper itself

Abstract

rationaleAsthma is associated with chronic changes in the airway epithelium, a key target of SARS-CoV-2. Many epithelial changes are driven by the type 2 cytokine IL-13, but the effects of IL-13 on SARS-CoV-2 infection are unknown.

objectivesWe sought to discover how IL-13 and other cytokines affect expression of genes encoding SARS-CoV-2-associated host proteins in human bronchial epithelial cells (HBECs) and determine whether IL-13 stimulation alters susceptibility to SARS-CoV-2 infection.

methodsWe used bulk and single cell RNA-seq to identify cytokine-induced changes in SARS-CoV-2-associated gene expression in HBECs. We related these to gene expression changes in airway epithelium from individuals with mild-moderate asthma and chronic obstructive pulmonary disease (COPD). We analyzed effects of IL-13 on SARS-CoV-2 infection of HBECs. MEASUREMENTS AND MAIN

resultsTranscripts encoding 332 of 342 (97%) SARS-CoV-2-associated proteins were detected in HBECs (≥1 RPM in 50% samples). 41 (12%) of these mRNAs were regulated by IL-13 (>1.5-fold change, FDR < 0.05). Many IL-13-regulated SARS-CoV-2-associated genes were also altered in type 2 high asthma and COPD. IL-13 pretreatment reduced viral RNA recovered from SARS-CoV-2 infected cells and decreased dsRNA, a marker of viral replication, to below the limit of detection in our assay. Mucus also inhibited viral infection.

conclusionsIL-13 markedly reduces susceptibility of HBECs to SARS-CoV-2 infection through mechanisms that likely differ from those activated by type I interferons. Our findings may help explain reports of relatively low prevalence of asthma in patients diagnosed with COVID-19 and could lead to new strategies for reducing SARS-CoV-2 infection.

Identifiers

PMID33655249
PMCPMC7924269
OpenAlexW3130646753

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.